Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



ICER Report: New MS Drugs More Effective, But Safety Concerns Abound

Three relatively new disease-modifying therapies (DMTs) —  Copaxone (alemtuzumab), Tysabri (natalizumab), and ocrelizumab — are significantly more effective than other DMTs in the reduction of relapses in relapsing-remitting multiple sclerosis (RRMS), according to the latest Institute for Clinical and Economic Review (ICER) evidence report.1

The ICER report included data from 33 trials of 10 US Food and Drug Administration (FDA)-approved DMTs for MS in the context of the therapeutic goal to decrease the frequency of relapses and prevent further disability. In comparing efficacy of all DMTs with safety, none of the agents in the ICER report were deemed “ideal.”

Annualized Relapse Rates Among DMTs

Three of the 4 relatively new DMTs (alemtuzumab, natalizumab, and ocrelizumab but not daclizumab) showed a reduction in the annualized relapse rate (ARR) of approximately 70% compared with placebo. The next most effective agents were fingolimod, daclizumab, rituximab, and dimethyl fumarate, collectively producing a 47% to 54% reduction in ARR. The lowest efficacy (17% to 37% reduction in ARR) was reported in a group of traditional therapies including interferons, glatiramer acetate 20 mg, and teriflunomide.

Slowing Disease Progression

The newly approved agents (including alemtuzumab, ocrelizumab, daclizumab, and natalizumab) showed the most benefits in slowing disability in RRMS compared with placebo (58%, 53%, 46%, and 44% reductions, respectively). Four older DMTs — interferon β-1a 30 mcg, interferon β-1a 22 mcg, teriflunomide 7 mg, and glatiramer acetate 40 mg — did not demonstrate significant improvements in disease progression. All others had moderate benefits.


The safest agents were interferons, glatiramer acetate, and teriflunomide. The least safe, due to the risk of progressive multifocal leukoencephalopathy (PML) in patients with positive testing results for the JC virus, were alemtuzumab and natalizumab. Several drugs, including teriflunomide, daclizumab, fingolimod, dimethyl fumarate, ocrelizumab, and natalizumab in JC virus-negative patients, were deemed to have moderate safety compared to all other DMTs.

Value of Therapy Compared to Supportive Care

The ICER group developed a simulation model to estimate the lifetime cost of a particular therapy, taking into account wholesale acquisition cost, dosing, administration, monitoring, and average discounts applied. The estimated lifetime drug cost was then used as a basis of comparison with the costs of supportive care that included inpatient and outpatient care from multiple relapses, disease progression, and ultimate mortality from RRMS. Using this model, the related health care costs over a patient's projected lifetime ranged from approximately $572,000 for alemtuzumab to $1.5 million for daclizumab, compared with approximately $333,300 for supportive care. The model took into account costs from relapses and prevented relapses in RRMS, as well as incremental costs-per-life-year gained and quality-adjusted life years.

Story Source: The above story is based on materials provided by NEUROLOGYADVISOR
Note: Materials may be edited for content and length

Labels: , ,

Go to Newer News Go to Older News